Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth hormone releasing hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: Growth hormone releasing hormone. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-000384-26 Sponsor Protocol Number: BPLG-005 Start Date*: 2005-11-10
    Sponsor Name:LG Life Science Ltd. [...]
    1. LG Life Science Ltd.
    2. BioPartners
    Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.0 10056438 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002892-16 Sponsor Protocol Number: NN8640-4054 Start Date*: 2014-10-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-00...
    Medical condition: Growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-004764-31 Sponsor Protocol Number: 02-2006 Start Date*: 2007-01-11
    Sponsor Name:Max Planck Institute of Psychiatry
    Full Title: Effects of corticotropin-releasing hormone on sleep electroencephalogram and sleep associated hormone secretion in young healthy women
    Medical condition: Healthy volunteers. The aim is to test the effects of CRH on sleep electroencephalogram and sleep associated secretion of growth hormone and cortisol
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002698-13 Sponsor Protocol Number: GX-H9-002 Start Date*: 2015-01-14
    Sponsor Name:Genexine, Inc
    Full Title: A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adu...
    Medical condition: Adult Growth Hormone Deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SE (Completed) DE (Completed) GR (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000929-42 Sponsor Protocol Number: TCH-306 Start Date*: 2021-06-09
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ...
    Medical condition: Adult Growth Hormone Deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002072-24 Sponsor Protocol Number: 15VR7 Start Date*: 2015-10-22
    Sponsor Name:Versartis Inc.
    Full Title: An Open-Label, Dose Finding, International Phase 2 Study with Once Monthly Subcutaneous Somavaratan (VRS-317) in Adult Growth Hormone Deficiency (GHD) Versartis International Trial in Adults with ...
    Medical condition: Growth Hormone Deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001681-25 Sponsor Protocol Number: 23681 Start Date*: 2015-07-15
    Sponsor Name:Merck KGaA
    Full Title: An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Ex...
    Medical condition: Small for Gestational Age
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005613-38 Sponsor Protocol Number: 44648368 Start Date*: 2006-05-31
    Sponsor Name:Dr. Chris Thompson
    Full Title: Assessment of platelet function in the hypopituitary population. Does hormone replacement therapy alter thrombotic risk?
    Medical condition: Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the pituitary gland or from diseases of the hypothalamus, which cause diminished secretion of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000830-37 Sponsor Protocol Number: CP-4-005 Start Date*: 2013-07-03
    Sponsor Name:OPKO Biologics Ltd.
    Full Title: A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency
    Medical condition: Adult or childhood onset growth hormone deficiency (GHD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GR (Completed) GB (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002125-42 Sponsor Protocol Number: CTH9507J Start Date*: 2004-09-22
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS
    Medical condition: EVALUATION OF GROWTH HORMONE RELEASE
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002471-11 Sponsor Protocol Number: Leuprorelin-4002 Start Date*: 2022-08-08
    Sponsor Name:Takeda (China) International Trading Co., Ltd.
    Full Title: An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-003233-16 Sponsor Protocol Number: TH9507-CTR-1012 Start Date*: 2007-09-19
    Sponsor Name:Theratechnologies Inc.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Su...
    Medical condition: HIV-associated lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024608 Lipodystrophy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Completed) BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002963-31 Sponsor Protocol Number: D-CN-52014-243 Start Date*: 2023-01-13
    Sponsor Name:Ipsen Pharma
    Full Title: AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TRIPTORELIN 3-MONTH FORMULATION IN CHINESE CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
    Medical condition: Central Precocious Puberty
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005444-88 Sponsor Protocol Number: TH9507-CTR-1011 Start Date*: 2007-01-16
    Sponsor Name:Theratechnologies Inc.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess A...
    Medical condition: HIV-associated lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024608 Lipodystrophy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003857-78 Sponsor Protocol Number: D-CN-52014-244 Start Date*: 2023-06-29
    Sponsor Name:Ipsen Pharma
    Full Title: A phase III, open-label, multicentre, single arm study to assess the efficacy and safety of the triptorelin 6-month formulation in Chinese paediatric participants with central precocious puberty
    Medical condition: Central Precocious Puberty
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003087-59 Sponsor Protocol Number: EFC6193 Start Date*: 2006-11-29
    Sponsor Name:sanofi aventis recherche et developpement
    Full Title: A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone ...
    Medical condition: Hormone Refractory Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) NL (Completed) SK (Completed) DK (Completed) SE (Completed) FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003247-70 Sponsor Protocol Number: UZAPED1 Start Date*: 2007-10-29
    Sponsor Name:Belgian Study Group for Pediatric Endocrinology
    Full Title: Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height.
    Medical condition: predicted short stature
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066333 Idiopathic short stature LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003142-32 Sponsor Protocol Number: TBR-760-NFPA-201 Start Date*: 2020-07-16
    Sponsor Name:Tiburio Therapeutics, Inc.
    Full Title: A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas
    Medical condition: Non-Functioning Pituitary Adenomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10035079 Pituitary adenoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002240-17 Sponsor Protocol Number: ATR-101-301 Start Date*: 2017-05-16
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome
    Medical condition: endogenous Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 14:13:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA